Abstract
AB Balazs, Y Ouyang, CM Hong. Nat Med. 2014;20(3):296–300 A large majority of new HIV infection results from transmission across mucosal barriers. HIV vaccine clinical trials have failed to illicit protective immunity to infection. Furthermore, pre-exposure and postexposure prophylaxis regimens have had limited success, primarily due to nonadherence to the prescribed regimens. Protection with currently available vaccines to mucosal infections, such as human papilloma virus and influenza virus, correlate with systemic neutralizing antibodies. The purpose of this study was to evaluate a new strategy for prevention of HIV transmission, “vectored immunoprophylaxis,” a specific form of gene transfer therapy in which the gene for a modified broadly neutralizing antibody is directed into …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
